We used a human lung adenocarcinoma cell line (A549) that was opsonized with cetuximab as a model for NK-mediated ADCC, because cetuximab is a hIgG1 anti-EGFR antibody capable of binding CD16a and enabling ADCC2. This evidence concerns the gene FCGR3A and lung adenocarcinoma.